Greater understanding of the biology and genetics of urothelial carcinoma is helping to identify and define the role of molecules and pathways appropriate for novel-targeted therapies. Here, we review the targeted therapies that have been reported or are in ongoing urothelial carcinoma clinical trials, and highlight molecular targets characterized in preclinical and clinical studies.
INTRODUCTION
In the United States in 2013, there were an estimated 72 500 new cases of, and 15 210 deaths from, urothelial carcinoma. Although urothelial carcinoma is considered chemotherapy-sensitive, very few patients with metastatic disease are cured. Patients with a good prognosis can expect a median survival of 12-14 months [1] . Approximately 70-80% of urothelial carcinoma is nonmuscle-invasive bladder cancer (NMIBC); the remaining 20-30% is muscleinvasive bladder cancer (MIBC) or metastatic. Almost 70% of patients with NMIBC will have disease recurrence within 2 years of diagnosis. Chemotherapy regimens for MIBC and first-line metastatic urothelial carcinoma contain cisplatin, including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), dose-dense MVAC, and gemcitabine and cisplatin. However, there is currently no standard second-line therapy for urothelial carcinoma [2,3 & ,4]. Several trials evaluating single chemotherapy agents, such as docetaxel, pemetrexed, gemcitabine, and paclitaxel have shown response rates of 9-27%, with 2-3-month progression-free survival (PFS) and no improvement in overall survival (OS). Multidrug regimens have shown higher response rates, but no OS benefit [5] [6] [7] [8] [9] .
A better understanding of the tumor biology and molecular patterns of urothelial carcinoma has led to clinical trials of several targeted therapies, including agents targeting angiogenesis, epidermal growth factor receptor (EGFR), and immunomodulatory agents. Research in immunotherapy and vaccines for urothelial carcinoma is in very early stages. Multiple tumor-associated antigens for vaccine targeting have been identified, but data on these agents are limited to safety, as their efficacy has not been demonstrated. Still, many targeted agents have been studied in all stages of urothelial carcinoma and many more are in ongoing clinical trials (Table 1) .
TARGETED AGENTS IN NONMUSCLE-INVASIVE BLADDER CANCER
The current standard of care for patients with newly diagnosed high-grade NMIBC is transurethral resection, followed by intravesical Bacillus Calmette-Guerin (BCG) over 6 weeks, followed by maintenance therapy. BCG has an initial failure rate of approximately 35% in terms of disease recurrence or progression. For the 20-35% of patients who fail an initial induction of BCG, a second 6-week cycle of BCG may be beneficial. However, patients who fail two courses often proceed to radical cystectomy [10, 11] . The majority of targeted therapies for NMIBC have been studied in patients who have failed intravesical BCG therapy.
Reported studies of targeted agents in nonmuscle-invasive bladder cancer
Several clinical trials using targeted therapy in NMIBC have been reported (Table 2a) [12, 13, 14 && ,15].
Two were phase I dose-escalation studies using intravesical oportuzumab monatox [13] and TMX-101 [14 && ]. Preliminary results from these trials show that the drugs are well tolerated, with no grade III-V adverse events. One phase II study was in patients who had failed BCG treatment and who were then treated with intravesical oportuzumab monatox targeting epithelial cell adhesion (EpCAM) [15] . A complete response was seen in 20 patients (44%) at the 3-month evaluation. In another phase II trial evaluating the use of intravesical apaziquone in the setting of intermediaterisk and high-risk NMIBC, the observed recurrence rate at 1 year was 34.7% [12] . The clinical impact of these early-phase trials will require further investigation.
Ongoing studies of targeted agents in nonmuscle-invasive bladder cancer
Targeted agents being studied in high-grade NMIBC include sunitinib (VEGFR-1,2 inhibitor), lenalidomide (immunomodulatory, antiangiogenic, and cytotoxic), recombinant melanoma-associated antigen (recMAGE)-A3 þ AS-15 (vaccine MAGE), and rituximab (CD20 antibody) in combination with intravesical BCG (Table 2b) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . TMX-101 (toll-like receptor 7 agonist) is also being evaluated as a first-line intravesical therapy in patients with NMIBC with carcinoma in situ. Two clinical trials are evaluating apaziquone (cytotoxic) and DTA-H19/PEI (H19 transcription factor) in lowrisk and intermediate-risk NMIBC, respectively. A phase 0 study is analyzing the use of valproic acid in the 4 weeks between tumor resection and initiation of intravesical therapy. Four ongoing trials in BCG-refractory patients are assessing ALT-801 (Altor Bioscience) [interleukin 2 (IL-2)/ T-cell receptor fusion protein that targets p53] combined with intravesical gemcitabine, everolimus [mammalian target of rapamycin (mTOR) inhibitor] in combination with intravesical gemcitabine, recombinant adenovirus mediated interferon (antiangiogenic and immunomodulatory), and dovitinib [fibroblast growth factor receptor 3 (FGFR-3) inhibitor] in tumors positive for FGFR-3 mutation or overexpression. HS-410 (Heat Biologics) is a clone of live urothelial carcinoma cells from a single tumor source that continuously secretes gp96, a chaperone protein. In turn, gp96 chaperones tumor antigens to T cells designed to induce a pan-tumor antigen immune response mediated by T cells. This is now being evaluated in a phase I/II study. The National Cancer Institute has initiated a study with an induction course of intravesical BCG in combination with a 'priming
KEY POINTS
A growing number of targeted agents are being studied in all stages of urothelial carcinoma, especially in the second-line setting.
Clinical trials of targeted therapies for urothelial carcinoma in an unselected patient population have been negative so far, although agents targeting angiogenesis appear to have some activity in a small number of patients.
For NMIBC, most ongoing trials are focusing on antitumor immunity using immunotherapeutic agents alone or with concurrent intravesical BCG.
Combination trials of TKIs and cytotoxic chemotherapy in MIBC and first-line metastatic urothelial carcinoma have reported significant toxicities.
Genomic studies reveal that urothelial carcinoma is a heterogeneous disease with a large number of somatic mutations that may provide targets for therapy and predict response to specific targeted agents.
vaccine' called PANVAC [PAN (all) VAC (vaccine)] , a subcutaneous immunomodulatory vaccine, in patients who have failed prior BCG therapy. PANVAC is a poxviral cancer vaccine that has demonstrated therapeutic efficacy against a variety of carcinomas. PANVAC consists of a primary vaccination with a replication-competent recombinant vacciniavector, followed by multiple boosts with a replication-incompetent recombinant fowlpox (rF) vector. These vectors contain transgenes for both human T-cell costimulatory molecules and tumor-associated antigens against mucin 1 (MUC-1) [30, 31] and (carcinoembryonic antigen) CEA [32] . MUC-1 and CEA are expressed in approximately 93 and 76% of high-grade bladder tumors, respectively.
TARGETED AGENTS IN MUSCLE-INVASIVE BLADDER CANCER
The primary therapy for MIBC is radical cystectomy and lymph node dissection. In randomized phase III trials, cisplatin-based neoadjuvant chemotherapy has demonstrated a survival benefit [33] [34] [35] over cystectomy alone [36, 37] by increasing the rate at which MIBC tumors (stage T2-T4a) are downstaged to NMIBC tumors (< T2). Several targeted agents for MIBC have been reported and are currently under investigation (Table 3) . Trials in the neoadjuvant setting have focused on combining VEGF agents with cisplatin-based chemotherapy. The data for adjuvant chemotherapy in MIBC are less compelling than for neoadjuvant chemotherapy, and there are limited data in the setting of persistent disease after BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ; EpCAM, epithelial cell adhesion molecule; FGFR, fibroblast growth factor receptor; MMC, mitomycin C; mTOR, mammalian target of rapamycin; n, number of patients enrolled; NR, not reported; PDGFR, platelet-derived growth factor receptor; PI, principal investigator; RR, response rate; TLR, toll-like receptor; VEGFR, vascular endothelial growth factor receptor. Table 3 .
Reported and ongoing trials of targeted agents in muscle-invasive bladder cancer Reported studies of targeted agents in muscle-invasive bladder cancer
Several clinical trials of targeted agents in MIBC have been reported (Table 3a and 3b) [38] [39] [40] [41] [42] [43] .
Two studies have used tyrosine kinase inhibitors (TKIs) as monotherapy in the neoadjuvant setting. Studies of erlotinib, which targets EGFR [44] , and dasatinib, which targets breakpoint cluster region/ abelson murine leukemia [45] , reported pathologic response rates (RRs) to less than pT2 of 35 and 14%, respectively. Two studies used bevacizumab (VEGF inhibitor and monoclonal antibody) with chemotherapy. One of those studies used dose-dense MVAC and reported a pathologic RR (< pT2) of 53% [38] . Two studies used sunitinib with chemotherapy in the neoadjuvant setting. One study was stopped early due to excess toxicity. The second study did not report excess toxicity, although cisplatin was split between days 1 and 8. Nevertheless, this study was stopped early as well due to lack of interest from the sponsoring drug company [46] .
Ongoing studies of targeted agents in muscle-invasive bladder cancer
The neoadjuvant setting is ideal for studying targeted therapy, as tissue can be analyzed for changes in protein expression and tumor morphology before and after treatment. Vaccine immunotherapy is a promising therapeutic approach for patients with MIBC, especially in the adjuvant setting wherein patients are at high risk of recurrence and have limited therapeutic choices after neoadjuvant chemotherapy. Agents being studied in the neoadjuvant and adjuvant settings are described in Table 3c and 3d [47,48,49 & ,50-59] .
TARGETED AGENTS IN METASTATIC UROTHELIAL CARCINOMA
Although first-line treatment of metastatic urothelial carcinoma with cisplatin-based chemotherapy may have RRs as high as 70%, duration of response is short (median PFS is about 7 months) [60] , highlighting the urgent need to improve treatment options in this setting. Multiple targeted agents used alone or in combination with chemotherapy have been studied in the first-line setting (Table 4a and 4b) [39, 45, 61, 62 && , [63] [64] [65] [66] [67] [68] [69] . Cumulative toxicities in a patient population that is frail at baseline have limited the success of first-line combination studies with targeted agents, particularly TKIs. Nevertheless, there are many ongoing trials of targeted agents as first-line therapy with chemotherapy in metastatic bladder cancer for cisplatin eligible (Table 4c ) [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] and cisplatin ineligible (Table 4d ). In the second-line setting, vinflunine, a microtubule-inhibiting vinca alkaloid, has been extensively investigated and was approved as a second-line therapy by the European Medicines Agency based on a modest survival benefit compared with best supportive care (6.9 vs. 4.3 months, P ¼ 0.04) [88] . In the United States, where the majority of targeted agents are studied ( Table 5 ), there is no approved second-line therapy for metastatic urothelial carcinoma.
Reported studies of targeted agents as first-line therapy in metastatic urothelial carcinoma
From 2007 to 2013, eight trials were reported using targeted agents in combination with chemotherapy for first-line treatment of metastatic urothelial carcinoma (Table 4a ). The agents studied included antiangiogenic agents (bevacizumab, sunitinib, and sorafenib) and EGFR-targeted agents (trastuzumab, gefitinib, and cetuximab). The addition of targeted agents to standard platinum-based regimens (with the exception of bevacizumab) has not demonstrated an improvement in OS compared with historical data. Three trials of targeted single agents as first-line treatment of metastatic urothelial carcinoma have been reported since 2010 (Table 4b) . Single-agent sunitinib in cisplatin-ineligible patients and single-agent sorafenib had less than 10% RRs in the first-line setting [89, 90] . Singleagent eribulin (microtubule inhibitor) reported a RR of 38% in the first-line setting [61] .
Reported and ongoing studies of targeted agents as second-line therapy in metastatic urothelial carcinoma
Patients who progress after platinum-based combination therapy have urothelial carcinoma tumors that are often resistant to other available therapies. In these patients, tumor shrinkage with targeted single agents has been low in reported studies with the majority of RR of less than 10% (Table  5b ) [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] . Similarly, the combination of targeted agents with chemotherapy has not shown significant improved RRs in this setting (Table 5a ) [91] [92] [93] .
A randomized phase II study of docetaxel and vandetanib (EGFR, VEGFR, and RET-TKI) compared with docetaxel alone did not show significant Table 5 .
Reported and ongoing trials of targeted agents as second-line therapy in metastatic bladder cancer [91] . A randomized phase II study of cetuximab (EGFR inhibitor) alone or in combination with paclitaxel reported a RR of 0% for cetuximab alone and 25% for the combination [92] . Even with the low activity of targeted agents reported in the second-line setting, the number of ongoing studies continues to rapidly grow (Table 5c and 5d) [53, [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] .
ANGIOGENESIS INHIBITION IN UROTHELIAL CARCINOMA
VEGF, one of the most important factors in angiogenesis, is increased in the tumor tissue, serum, and urine of patients with urothelial carcinoma and correlates with tumor stage and survival [9, [119] [120] [121] . Higher levels of VEGF in the tumors and serum of patients with urothelial carcinoma correlate with worse prognosis and higher likelihood of disease recurrence. Angiogenesis inhibitors have been shown in vitro to be active in urothelial carcinoma cells. VEGF signaling occurs through binding of its receptors VEGFR1 (fms-like tyrosine kinase-1) and VEGFR2 (fetal liver kinase-1). In a preclinical study, six of 13 urothelial carcinoma cell lines examined expressed VEGFR2. Further analysis of the T24 urothelial carcinoma cell line revealed a functional autocrine loop involving VEGF and VEGFR2 [122] .
One study revealed that VEGF and VEGFR1 expression was higher in NMIBC compared with MIBC specimens (P < 0.001), possibly due to a higher rate of cell growth in early stages of disease, whereas VEGFR2 was significantly higher in MIBC, as compared with NMIBC (P < 0.001) [123 && ]. VEGFR inhibition has been shown to decrease proliferation and invasion of urothelial carcinoma cells, leading to the investigation of VEGF-targeted agents in urothelial carcinoma.
Bevacizumab in urothelial carcinoma
Phase II trials of bevacizumab in combination with chemotherapy have shown promising results in urothelial carcinoma compared with historical data. A phase II study of first-line gemcitabine, cisplatin, and bevacizumab showed a RR of 72% and an OS of 19.1 months in metastatic urothelial carcinoma [45] . Another phase II study of first-line gemcitabine, carboplatin, and bevacizumab in cisplatinineligible patients with metastatic urothelial carcinoma showed a RR of 49% and an OS of 13.9 months [62 && ]. This study compared survival in patients who received bevacizumab with gemcitabine and carboplatin to a contemporary control population that ALK1, activin receptor-like kinase 1; EGFR, epidermal growth factor receptor; ER, estrogen receptor; FGFR, fibroblast growth factor receptor; HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin; n, number of patients enrolled; NR, not reported; OS, overall survival; PDGFR, platelet-derived growth factor receptor; PI, principal investigator; RR, response rate; SAHA, suberanilohydroxamic acid; TGFbR, transforming growth factor b receptor; VEGFR, vascular endothelial growth factor receptor.
received gemcitabine and carboplatin alone during the same time the study was conducted. The study group that received bevacizumab had an OS of 13.9 vs. 10.3 months in the contemporary population that did not receive bevacizumab. A third phase II study of neoadjuvant dose-dense MVAC and bevacizumab in MIBC had a pathologic RR of 53% [38] , which is higher than the pathologic RR reported with neoadjuvant MVAC. An ongoing study in MIBC of neoadjuvant gemcitabine and cisplatin with bevacizumab followed by adjuvant paclitaxel with bevacizumab has completed accrual [52] . An ongoing Cancer And Leukemia Group B/Alliance phase III study of first-line gemcitabine and cisplatin with or without bevacizumab in patients with metastatic urothelial carcinoma is nearing its anticipated accrual of 500 patients.
Sunitinib in urothelial carcinoma
Sunitinib, an oral multiple-receptor TKI approved for use in many types of solid tumors, was one of the first targeted agents to be studied in advanced urothelial carcinoma. Sunitinib targets VEGF receptors, stem cell factor receptor (KIT), platelet-derived growth factor receptor, RET, Fms-like tyrosine kinase 3, and colony-stimulating factor 1 receptor. It has been shown to be active against urothelial carcinoma cells in vitro and in vivo [124, 125] . A phase II second-line study of 77 patients with urothelial carcinoma showed radiographic tumor regression and a clinical benefit (partial response and stable disease) of 43% with sunitinib [89] . However, subsequent studies of sunitinib, including a first-line combination study, two neoadjuvant combinations studies [39] , and a maintenance study [46] , showed low responses and high toxicity with combined sunitinib and chemotherapy. There is an ongoing study of sunitinib administered with BCG in highgrade NMIBC, but no ongoing studies in MIBC or metastatic urothelial carcinoma. However, there are multiple ongoing studies with other VEGF TKIs, including sorafenib, pazopanib, and cabozantinib in urothelial carcinoma.
Epidermal growth factor receptor/human epidermal growth factor receptor 2 in urothelial carcinoma EGFR plays a significant role in mediating angiogenesis by regulating the activity of IL-8, VEGF, and basic fibroblast growth factor. Overexpression of EGFR leads to activation of the Ras signaling cascade, which leads to cell proliferation. Similar to VEGFR, EGFR is overexpressed in urothelial carcinoma and correlates with tumor stage, grade, prognosis, and survival [126] . Gefitinib, a selective EGFR inhibitor, was approved by the US Food and Drug Administration (FDA) for use in nonsmall cell lung cancer in 2003. Gefitinib has the potential to be effective in other solid tumors with increased EGFR expression, such as urothelial carcinoma. However, a phase II trial of gefitinib added to standard firstline gemcitabine and cisplatin showed no improvement in OS [127] . Gefitinib and lapatinib (dual TKI-targeting HER2/neu and EGFR) have been tested as single agents in the second-line treatment of metastatic urothelial carcinoma, and both agents demonstrated RRs of less than 5% [97, 98] . HER2/neu is the most studied of the four receptors in the EGFR family. HER2/neu regulates multiple processes, including cell proliferation. HER2/neu þ urothelial carcinoma patients have more advanced disease and more sites of metastasis [63] . HER2/neu þ patients with MIBC have a lower median OS than HER2/neupatients (33 vs. 50 months, respectively). However, results have been mixed, as a different study found that overexpression of HER2/neu in the primary tumor or any metastatic tumors was not predictive of survival [128] . A phase II study of trastuzumab (HER2/neu receptor-targeted monoclonal antibody), paclitaxel, carboplatin, and gemcitabine in HER2 þ urothelial carcinoma showed an OS of 14.1 months [63] . Trastuzumab is being evaluated in combination with paclitaxel and radiotherapy for bladder conservation. Multiple ongoing trials are testing the HER2 axis in metastatic urothelial carcinoma, including a study of first-line lapatinib in combination with gemcitabine and cisplatin [70] , a randomized phase II/III trial of second-line, singleagent lapatinib [106] , a combination study of secondline lapatinib and docetaxel [107] , and a vaccine study in HER2 þ urothelial carcinoma [53] .
NOVEL PATHWAYS AND AGENTS BEING STUDIED IN UROTHELIAL CARCINOMA
Multiple novel pathways and molecules that could potentially be targeted in urothelial carcinoma are being explored in preclinical and clinical studies; some of these include multiple receptor tyrosine kinases, MET, phosphatidylinositide 3-kinases (PI3K), heat shock proteins (HSPs), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and prostate stem cell antigen (PSCA).
Cabozantinib in urothelial carcinoma
Cabozantinib, an oral agent that primarily targets MET and VEGFR2, has been shown to prevent angiogenesis and invasive growth by inhibiting hepatocyte growth factor (HGF)-induced MET signaling in urothelial carcinoma cell lines. MET, a proto-oncogene that encodes for the HGF receptor [129 && ], is usually expressed by cells of epithelial origin. Activation of the MET receptor by HGF leads to downstream activation of multiple cytokines involved in motility, matrix remodeling, angiogenesis, survival, and proliferation leading to invasive growth of cancer cells [130] . Soluble urinary MET levels are elevated in urothelial carcinoma and correlate with disease stage. Plasma HGF levels are frequently elevated in advanced urologic malignancies [131] .
Urothelial carcinoma cell lines respond to HGF stimulation with increased activation of established intracellular signaling mediators [132] . HGF stimulation also increases invasion, growth rate, and anchorage-independent growth [133] . Cabozantinib reverses these HGF-driven activities and has shown activity in multiple solid tumors in phase I, II, and III clinical trials [134, 135] . The efficacy of cabozantinib in advanced urothelial carcinoma is being studied for the first time in an ongoing phase II trial [136] , wherein patients receive cabozantinib (60 mg/day) continuously in 28-day cycles. The study has three cohorts: metastatic urothelial carcinoma with measurable disease, bone-only metastatic urothelial carcinoma, and metastatic rare histology of the bladder, urethra, ureter, or renal pelvis.
Buparlisib (BKM120) in advanced urothelial carcinoma
PI3Ks are enzymes involved in regulating multiple cellular functions, including growth, proliferation, motility, and differentiation. PI3K mutations are found in urothelial carcinoma, and this pathway is a potential therapeutic target. BKM120, a PI3K inhibitor, has shown activity in multiple solid tumors [137, 138] and is currently undergoing phase III testing in breast cancer. There is also an ongoing phase II study of BKM120 in urothelial carcinoma [108], with the primary objective of PFS.
Apatorsen (OGX-427) in metastatic urothelial carcinoma
HSPs regulate the folding and unfolding of other proteins and are induced by exposure to elevated temperature or stress. OGX-427, an inhibitor of HSP27, inhibits apoptosis via cell death and proteotoxic stress pathways [47] . Ongoing studies include a multicenter randomized phase II trial [71] of first-line OGX-427 and gemcitabine and cisplatin vs. placebo in advanced urothelial carcinoma, and a multicenter randomized phase II study of second-line OGX-427 and docetaxel vs. docetaxel alone [139] .
Ipilimumab in metastatic urothelial carcinoma
Ipilimumab is an inhibitor of CTLA-4, a protein receptor on the surface of T cells that regulates T-cell activity by transmitting inhibitory signals. CD28, a costimulatory protein expressed on T cells, transmits stimulatory signals to T cells. Activation of T-cell receptors via CD28 leads to increased CTLA-4 expression. Ipilimumab interrupts the inhibitory process that prevents cytotoxic T lymphocytes from destroying tumor cells. By interrupting the inhibition of T cells mediated by CTLA-4, cytotoxic T lymphocytes are able to recognize and destroy tumor cells [72] . A multicenter phase II trial of ipilimumab with gemcitabine and cisplatin [140] is ongoing in patients with metastatic urothelial carcinoma. In this trial, patients with stable or responding disease continue ipilimumab maintenance therapy after completing six cycles of chemotherapy. There are also several ongoing checkpoint inhibitor phase I studies with bladder cancer expansion cohorts. These studies will help assess the activity of immune checkpoint blockade in metastatic urothelial carcinoma.
Prostate stem cell antigen as a therapeutic target in urothelial carcinoma
PSCA is a novel therapeutic target for urothelial carcinoma in carriers of the rs2294008-T allele [141] . A genetic variant (rs2294008) discovered by urothelial carcinoma genome-wide association studies is a strong predictor of PSCA protein expression in bladder tumors [142 & ]. Carriers of the T allele have been shown to be at higher risk of urothelial carcinoma [143] , and urothelial carcinoma patients with the T allele have higher expression of PSCA mRNA and protein in tumors. The T allele predicts PSCA expression in tumors of all stages and tumor grades. Therefore, PSCA may be a promising therapeutic target, and genetic testing may be useful in selecting patients for treatment. An anti-PSCA monoclonal antibody is currently being tested in clinical trials [144, 145] .
THE FUTURE OF TARGETED THERAPIES FOR ADVANCED UROTHELIAL CARCINOMA
Targeted therapies currently being studied in advanced urothelial carcinoma have shown efficacy in other solid tumors. Cancer therapy continues to transition from cytotoxic to targeted therapies. There is a lot of genetic diversity and heterogeneity within tumor types, consequently, specific subsets of patients may have a greater benefit from targeted therapies. In addition, tumor cells can adapt to targeted therapies by developing resistance, usually through mutations in target enzymes and cell-death pathways, or by developing new methods of drug efflux. Therefore, researchers are developing even more selective targets, identified in individual tumors through genomic analysis.
The Bladder Cancer Analysis Working Group of The Cancer Genome Atlas (TCGA) analyzed 131 samples of MIBC and identified 32 significantly mutated genes, the most common of which were P53 (49%), MLL2 (27%), ARID1A (25%), KDM6A (24%), and PIK3CA (20%). The majority (69%) of tumors were found to harbor potential therapeutic targets with a mean and median somatic mutation rate per tumor of 7.7 and 5.5 per megabase, respectively. The analysis also showed that mutations in chromatin-modifying genes were enriched, and that the chromatin-modifying genes MLL2, ARID1A, and KDM6A were inactivated at high frequency in urothelial carcinoma. Significantly, ERBB2 (Her-2/neu) was mutated or amplified in 9% of samples, suggesting a possible role for ERBB2 as a therapeutic target in bladder cancer using similar treatment strategies that target ERBB2 amplified breast cancers [146 && ].
Genomic sequencing studies may also be useful in the clinical setting by revealing new potential drug targets as well as mutations that may predict responsiveness to specific targeted therapies. A study that analyzed 97 high-grade bladder tumors identified several genomic alterations in molecular pathways that could be potential drug targets. In this study, 61% of the tumors analyzed had potential actionable drug targets due to mutations in the RTK-RAS-RAF and PI3K/AKT/mTOR pathways. Tumors with high burden of DNA copy number alterations were found to have more mutations in TP53 and RB1 [147 && ]. Another study analyzed 13 bladder cancer patients treated with everolimus, a mTOR-targeted agent. TSC1 (tuberous sclerosis complex 1), which codes for TSC1 protein, a regulator of mTOR signaling, has been shown to be mutated in some bladder cancers [148] . In this study, two of three patients with nonsense mutations in TSC1 gene had some degree of response to everolimus, one patient with missense mutation in TSC1, which is of unknown functional significance, had some tumor response to everolimus, and eight of nine patients with progressive disease were TSC1 wildtype [149 & ]. The data obtained from these studies can help target therapies more specifically to tumors based on a large panel of mutational analysis and possibly predict responsiveness to targeted therapies based on the presence of specific mutations -a possible future direction for targeted therapy for urothelial carcinoma.
CONCLUSION
Targeting molecular aberrations has revolutionized the clinical management of multiple cancers. Significant progress has been made in the last few years in testing targeted agents in all stages of urothelial carcinoma, from NMIBC to advanced refractory metastatic urothelial carcinoma. However, clinical trial results of targeted therapies in urothelial carcinoma in unselected patient populations have been negative so far. Therefore, there have been no reported phase III studies nor FDA-approved targeted therapeutic agents for use in urothelial carcinoma. The focus of treatment for NMIBC in ongoing clinical trials is enhancing antitumor immunity with immunotherapeutic agents alone or with concurrent intravesical BCG therapy. Combination trials of TKIs and cytotoxic chemotherapy in MIBC and first-line metastatic urothelial carcinoma have reported significant toxicities. However, targeting angiogenesis via either the VEGF or mTOR pathways has demonstrated activity in a small number of urothelial carcinoma patients [148] . Studies of genomic alterations confirm that urothelial carcinoma is a heterogeneous disease driven by a large array of somatic mutations that may predict responsiveness to specific targeted therapies. In the future, improved understanding of the biology and genetics of urothelial carcinoma may lead to personalized therapies for specific molecular targets that will improve therapeutic outcomes.
